ANI Pharmaceuticals CFO sells 2,850 shares under plan

Accepted by SEC EDGAR 07/30/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on July 29, 2026 at a weighted average price of $81.36 per share in open-market or private transactions. The trades, priced between $80.61 and $81.88, were executed under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following the sale, Carey directly holds 174,693 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,850 shares

Net Sell 1 txn

Insider CAREY STEPHEN P.

Role SVP & CFO

Sold 2,850 shs ($232K)

Share of Position Sold 1.6%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,850	$81.36	$232K

Holdings After Transaction: Common Stock — 174,693 shares (Direct)

Holdings Before and After: Common Stock, 177,543 to 174,693 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. F2. The shares were sold in multiple trades at prices ranging from $80.61 to $81.88. The price reported above reflects the weighted average sales price.

Key Figures

Shares sold: 2,850 shares Weighted average sale price: $81.36 per share Sale price range: $80.61–$81.88 per share +2 more

5 metrics

Shares sold 2,850 shares Common stock sale on July 29, 2026 by SVP & CFO Stephen P. Carey

Weighted average sale price $81.36 per share Weighted average price across multiple trades in the July 29, 2026 sale

Sale price range $80.61–$81.88 per share Price range of multiple trades comprising the reported sale

Shares owned after sale 174,693 shares Direct common stock holdings of Stephen P. Carey following the transaction

Rule 10b5-1 plan adoption date March 6, 2026 Date the reporting person adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, Sale in open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"The price reported above reflects the weighted average sales price"

Sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANI Pharmaceuticals (ANIP) CFO Stephen P. Carey report in this Form 4 filing?

Stephen P. Carey reported a sale of 2,850 shares of ANI Pharmaceuticals common stock. The transactions occurred on July 29, 2026 at a weighted average price of $81.36 per share under a Rule 10b5-1 trading plan.

How many ANI Pharmaceuticals (ANIP) shares did the CFO sell and at what prices?

The CFO sold 2,850 shares of ANI Pharmaceuticals common stock. The shares were sold in multiple trades at prices ranging from $80.61 to $81.88, with a reported weighted average sales price of $81.36 per share.

What are Stephen P. Carey’s ANI Pharmaceuticals (ANIP) holdings after this reported sale?

After the reported transactions, Stephen P. Carey directly holds 174,693 shares of ANI Pharmaceuticals common stock. This figure reflects his post-transaction direct ownership as disclosed in the Form 4 filing for the July 29, 2026 sale.

Was the ANI Pharmaceuticals (ANIP) CFO’s stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted on March 6, 2026 by the reporting person, and the Form 4 also checks the Rule 10b5-1 plan affirmation box.

What transaction type is reported for ANI Pharmaceuticals (ANIP) CFO in this Form 4?

The Form 4 reports a Code S transaction, described as a sale in open market or private transaction of common stock. It covers 2,850 shares sold on July 29, 2026, with resulting direct ownership of 174,693 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2026		S(1)		2,850	D	$81.36(2)	174,693	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

2. The shares were sold in multiple trades at prices ranging from $80.61 to $81.88. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)